A detailed history of Two Sigma Investments, LP transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 25,089 shares of VRCA stock, worth $199,457. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,089
Holding current value
$199,457
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.74 - $6.81 $118,921 - $170,856
25,089 New
25,089 $148,000
Q3 2023

Nov 14, 2023

SELL
$3.75 - $7.46 $18,000 - $35,808
-4,800 Reduced 6.92%
64,558 $250,000
Q2 2023

Aug 14, 2023

BUY
$5.32 - $6.79 $118,449 - $151,179
22,265 Added 47.28%
69,358 $400,000
Q1 2023

May 15, 2023

SELL
$2.88 - $8.51 $10,733 - $31,716
-3,727 Reduced 7.33%
47,093 $306,000
Q4 2022

Feb 14, 2023

BUY
$2.09 - $3.39 $4,027 - $6,532
1,927 Added 3.94%
50,820 $139,000
Q3 2022

Nov 14, 2022

SELL
$2.17 - $4.3 $11,661 - $23,108
-5,374 Reduced 9.9%
48,893 $143,000
Q2 2022

Aug 15, 2022

BUY
$1.81 - $8.93 $98,223 - $484,604
54,267 New
54,267 $104,000
Q3 2021

Nov 15, 2021

SELL
$9.55 - $13.96 $155,817 - $227,771
-16,316 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$9.77 - $15.33 $31,420 - $49,301
3,216 Added 24.55%
16,316 $184,000
Q1 2021

May 17, 2021

BUY
$10.51 - $17.46 $137,681 - $228,726
13,100 New
13,100 $198,000
Q2 2020

Aug 14, 2020

SELL
$9.02 - $15.12 $159,915 - $268,062
-17,729 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$7.14 - $16.86 $168,618 - $398,165
-23,616 Reduced 57.12%
17,729 $194,000
Q4 2019

Feb 14, 2020

BUY
$13.08 - $17.43 $540,792 - $720,643
41,345 New
41,345 $657,000
Q4 2018

Feb 14, 2019

SELL
$6.75 - $16.12 $117,207 - $279,907
-17,364 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$13.94 - $19.88 $242,054 - $345,196
17,364 New
17,364 $282,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.